TriSalus Life Sciences, Inc.
TLSI
$5.73
$0.081.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 59.00% | 67.91% | 67.75% | 68.96% | 49.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 59.00% | 67.91% | 67.75% | 68.96% | 49.31% |
| Cost of Revenue | 57.50% | 22.19% | 3.49% | 14.59% | 15.42% |
| Gross Profit | 59.25% | 77.76% | 83.83% | 82.16% | 56.85% |
| SG&A Expenses | 20.94% | 29.40% | 42.79% | 51.40% | 43.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.40% | 6.90% | 30.21% | 42.54% | 40.53% |
| Operating Income | 27.82% | 13.62% | -16.86% | -33.65% | -37.54% |
| Income Before Tax | 49.32% | -20.32% | -3.29% | -35.02% | -25.69% |
| Income Tax Expenses | -33.33% | -42.86% | -21.43% | 325.00% | 0.00% |
| Earnings from Continuing Operations | 49.32% | -20.30% | -3.29% | -35.04% | -25.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.32% | -20.30% | -3.29% | -35.04% | -25.68% |
| EBIT | 27.82% | 13.62% | -16.86% | -33.65% | -37.54% |
| EBITDA | 28.32% | 14.12% | -16.79% | -33.47% | -37.75% |
| EPS Basic | 96.51% | 97.75% | 98.16% | 62.65% | 62.72% |
| Normalized Basic EPS | 95.34% | 97.64% | 97.17% | 62.16% | 62.03% |
| EPS Diluted | 96.51% | 97.75% | 98.16% | 62.65% | 62.72% |
| Normalized Diluted EPS | 95.34% | 97.64% | 97.17% | 62.16% | 62.03% |
| Average Basic Shares Outstanding | 91.03% | 221.86% | 384.45% | 106.86% | 117.02% |
| Average Diluted Shares Outstanding | 91.03% | 221.86% | 384.45% | 106.86% | 117.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |